Second-line small cell lung cancer clinical-trial update offering topline results and thoughtful context about implications for patients and clinicians.
Key Takeaways
- No new safety signals were identified with Zepzelca monotherapy or in combination with irinotecan
- "Relapsed SCLC is an aggressive cancer with a poor prognosis and patients continue to need treatment options
- Approval of Zepzelca in 2025 is based on the Phase 3 IMforte trial